newsfilter
← Latest News
Business Wire·

Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer's Disease

Alpha Cognition Inc. (CSE:ACOG) (OTCQB:ACOGF) (Alpha Cognition "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce